뇌졸중 임상시험 현황 : 동향과 분석(2026년판)

Clinical development is increasingly focused on improving functional recovery, reducing disability, enhancing reperfusion strategies, and preventing recurrent cerebrovascular events. Advances in imaging technologies, regenerative medicine, artificial intelligence, and precision medicine continue to reshape the stroke clinical trial landscape.

Stroke remains one of the leading causes of mortality and long-term disability worldwide, with ischemic stroke accounting for the majority of clinical development activity. Current research is centered on optimizing thrombolytic therapy, mechanical thrombectomy, neuroprotection, stem cell therapy, and secondary prevention strategies. Clinical trials analysis provides valuable insights into investigational therapies, pipeline maturity, trial phases, sponsor activities, regulatory developments, enrollment trends, and commercialization opportunities.

Market Drivers

Rising Global Burden of Stroke

The increasing incidence of stroke associated with aging populations, hypertension, diabetes, obesity, atrial fibrillation, and other cardiovascular risk factors continues to drive demand for innovative therapeutic approaches. The substantial clinical and economic burden of stroke is encouraging greater investment in neurological drug development.

Expansion of Neuroprotective Therapy Development

Growing research into neuroprotective agents aims to preserve brain tissue during acute ischemic stroke and improve long-term neurological recovery. Several investigational therapies are progressing through mid- and late-stage clinical development.

Advances in Reperfusion Strategies

Ongoing clinical trials continue to optimize thrombolytic agents, mechanical thrombectomy techniques, and imaging-guided intervention strategies to improve treatment outcomes and expand eligibility for acute stroke therapies.

Increasing Adoption of Digital Clinical Trials

Artificial intelligence, digital health platforms, wearable monitoring devices, telemedicine, and decentralized clinical trial models are improving patient recruitment, monitoring, and data collection while increasing operational efficiency.

Market Restraints

Complex Clinical Trial Design

Stroke clinical trials require large patient populations, rapid enrollment, standardized imaging protocols, and long-term functional outcome assessments, making development expensive and operationally complex.

Stringent Regulatory Requirements

Regulatory agencies require strong evidence demonstrating meaningful improvements in neurological recovery, functional independence, and long-term safety before approving new stroke therapies.

Patient Recruitment Challenges

The narrow therapeutic window for acute stroke treatment and strict patient eligibility criteria continue to create enrollment challenges for many clinical studies.

Clinical Trial and Technology Insights

The global stroke clinical trials market can be segmented by clinical trial phase, stroke type, therapy type, mechanism of action, sponsor type, route of administration, and geography.

By clinical trial phase, the market includes Phase I, Phase II, Phase III, and Phase IV trials. Phase II and Phase III studies account for the largest share of ongoing development activity as sponsors evaluate efficacy, safety, and functional outcomes in larger patient populations.

By stroke type, the market comprises ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke dominates clinical development because it represents the majority of stroke cases and offers numerous opportunities for therapeutic innovation.

By therapy type, investigational programs include thrombolytic therapies, neuroprotective therapies, regenerative medicine, stem cell therapies, anticoagulants, antiplatelet therapies, anti-inflammatory therapies, and combination treatments. Neuroprotective and regenerative therapies are emerging as important areas of research because they aim to improve neurological recovery beyond reperfusion alone.

By mechanism of action, pipeline therapies target thrombus dissolution, neuronal protection, vascular repair, inflammation modulation, neuroregeneration, and secondary stroke prevention.

By sponsor type, the market includes pharmaceutical companies, biotechnology firms, academic institutions, government organizations, and contract research organizations (CROs). Collaborative partnerships between academia and industry continue to accelerate clinical development.

By route of administration, investigational therapies include intravenous, oral, intra-arterial, injectable, and device-assisted interventions. Intravenous therapies remain central to acute stroke management, while oral therapies dominate secondary prevention.

Technological advances including artificial intelligence-assisted imaging, advanced neuroimaging biomarkers, digital health platforms, decentralized clinical trials, wearable monitoring systems, and electronic patient-reported outcomes are improving trial efficiency and supporting precision medicine approaches.

Clinical Trial Trends

The stroke clinical trial landscape continues to evolve toward personalized and technology-enabled neurological care.

Key trends include:

• Expansion of Phase II and Phase III clinical development.
• Increasing investment in neuroprotective therapies.
• Growing use of regenerative medicine and stem cell therapies.
• Broader adoption of artificial intelligence in clinical trial design.
• Expansion of decentralized and digital clinical trials.
• Increasing use of imaging biomarkers for patient selection.
• Greater emphasis on functional recovery and long-term neurological outcomes.

Regional Insights

North America remains the leading region for stroke clinical trials because of advanced stroke care infrastructure, extensive research funding, well-established regulatory pathways, and strong participation from pharmaceutical and biotechnology companies. Comprehensive stroke centers and academic institutions continue to support large multicenter studies.

Europe maintains a significant position through multinational clinical collaborations, strong academic research networks, and established stroke registries. Regulatory harmonization and large patient populations support continued clinical development.

Asia-Pacific is expected to experience the fastest growth owing to rising stroke incidence, expanding healthcare infrastructure, increasing research investment, and growing participation in multinational clinical trials across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are increasingly participating in multinational stroke studies as healthcare infrastructure and clinical research capabilities continue to improve.

Competitive Landscape

The stroke clinical trials landscape includes multinational pharmaceutical companies, biotechnology firms, academic medical centers, government research organizations, and contract research organizations.

Organizations continue investing in neuroprotective therapies, regenerative medicine, artificial intelligence, advanced imaging technologies, precision medicine, and digital clinical trial platforms. Strategic collaborations, licensing agreements, mergers and acquisitions, and global multicenter trials remain important strategies for accelerating clinical development and strengthening competitive positioning.

Future Outlook

The future of stroke clinical trials will be driven by advances in precision neurology, regenerative medicine, artificial intelligence, digital health, and personalized therapeutics. Continued research into neuroprotection, stem cell therapies, novel thrombolytics, and imaging-guided treatment is expected to improve functional recovery while expanding future commercialization opportunities.

Greater integration of decentralized trial models, real-world evidence, wearable technologies, and biomarker-guided patient selection is expected to enhance trial efficiency and accelerate regulatory approvals through 2035.

Conclusion

The global Stroke Clinical Trials Analysis market is expected to experience sustained growth through 2035, supported by increasing investment in neurological research, advances in neuroprotective therapies, expanding use of precision medicine, and continuous innovation in acute stroke management. Although challenges related to trial complexity, patient recruitment, and regulatory requirements remain, ongoing advances in artificial intelligence, regenerative medicine, and digital clinical research are expected to transform stroke drug development and improve patient outcomes.

Key Benefits of this Report

• Comprehensive analysis of the global stroke clinical trials landscape.
• Detailed evaluation of investigational therapies, clinical trial phases, and pipeline maturity.
• Competitive assessment of sponsor activities, strategic collaborations, and development trends.
• Insights into regulatory developments, emerging technologies, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, contract research organizations, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Clinical development planning, pipeline benchmarking, competitive intelligence, licensing and partnership evaluation, investment analysis, regulatory strategy, portfolio optimization, commercialization planning, and strategic decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global stroke clinical trials landscape by clinical trial phase, stroke type, therapy type, mechanism of action, sponsor type, route of administration, and geography
• Evaluation of investigational therapies, clinical development progress, pipeline maturity, enrollment trends, sponsor activities, and emerging technologies
• Assessment of regulatory developments, strategic collaborations, licensing agreements, mergers and acquisitions, and commercialization strategies
• Analysis of neuroprotective therapies, thrombolytics, regenerative medicine, stem cell therapies, artificial intelligence, digital clinical trials, and future development opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Stroke Clinical Development Landscape Overview
• 1.3 Key Pipeline Intelligence Highlights
• 1.4 Clinical Innovation Trends
• 1.5 Mechanism of Action Evolution
• 1.6 Risk-Adjusted Pipeline Assessment
• 1.7 Competitive Positioning Snapshot
• 1.8 Expected Regulatory and Commercial Milestones
• 1.9 Strategic Conclusions

2. Pipeline Overview

• 2.1 Stroke Therapeutics Pipeline Overview
  • 2.1.1 Pipeline Asset Distribution by Development Phase
  • 2.1.2 Historical Pipeline Growth Trends
  • 2.1.3 Active versus Inactive Programs
  • 2.1.4 Emerging Clinical Development Trends
• 2.2 Pipeline Assets by Sponsor Type
  • 2.2.1 Large Pharmaceutical Companies
  • 2.2.2 Biotechnology Companies
  • 2.2.3 Academic and Research Organizations
• 2.3 Pipeline Assets by Indication
  • 2.3.1 Acute Ischemic Stroke
  • 2.3.2 Hemorrhagic Stroke
  • 2.3.3 Secondary Stroke Prevention
  • 2.3.4 Post-Stroke Recovery and Rehabilitation
  • 2.3.5 Neuroprotection in Stroke
• 2.4 Pipeline Assets by Route of Administration
• 2.5 Pipeline Assets by Molecule Type
• 2.6 Pipeline Assets by Geographic Origin
• 2.7 Pipeline Maturity Assessment
• 2.8 Pipeline Productivity Analysis

3. Disease & Unmet Need Analysis

• 3.1 Disease Overview
  • 3.1.1 Stroke Classification
  • 3.1.2 Disease Burden Assessment
  • 3.1.3 Epidemiological Overview
• 3.2 Current Treatment Landscape
  • 3.2.1 Standard of Care Analysis
  • 3.2.2 Approved Pharmacological Interventions
  • 3.2.3 Mechanical and Procedural Interventions
• 3.3 Unmet Clinical Needs
  • 3.3.1 Acute Intervention Gaps
  • 3.3.2 Neuroprotection Challenges
  • 3.3.3 Long-Term Recovery Limitations
  • 3.3.4 Recurrence Prevention Challenges
• 3.4 Future Therapeutic Opportunities
• 3.5 Innovation White Space Analysis

4. Mechanism & Modality Landscape

• 4.1 Mechanism of Action Landscape
  • 4.1.1 Antithrombotic Therapies
  • 4.1.2 Thrombolytic Agents
  • 4.1.3 Neuroprotective Agents
  • 4.1.4 Anti-Inflammatory Mechanisms
  • 4.1.5 Vascular Repair Mechanisms
  • 4.1.6 Neuroregenerative Mechanisms
  • 4.1.7 Stem Cell-Based Mechanisms
  • 4.1.8 Emerging Novel Mechanisms
• 4.2 Mechanism Clustering Analysis
  • 4.2.1 Established Mechanisms
  • 4.2.2 Novel Mechanisms
  • 4.2.3 First-in-Class Candidates
  • 4.2.4 Best-in-Class Candidates
• 4.3 Modality Landscape
  • 4.3.1 Small Molecules
  • 4.3.2 Biologics
  • 4.3.3 Cell Therapies
  • 4.3.4 Gene Therapies
  • 4.3.5 RNA-Based Therapies
  • 4.3.6 Combination Therapies
• 4.4 Innovation Index Assessment
• 4.5 Mechanism-Based Competitive Benchmarking

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape Overview
• 5.2 Clinical Trial Activity by Phase
  • 5.2.1 Preclinical Programs
  • 5.2.2 Phase I Programs
  • 5.2.3 Phase II Programs
  • 5.2.4 Phase III Programs
  • 5.2.5 Filed and Under Regulatory Review Programs
• 5.3 Trial Design Benchmarking
  • 5.3.1 Sample Size Analysis
  • 5.3.2 Primary Endpoint Analysis
  • 5.3.3 Secondary Endpoint Analysis
  • 5.3.4 Duration Benchmarking
  • 5.3.5 Patient Selection Criteria
• 5.4 Recruitment Intelligence
  • 5.4.1 Enrollment Trends
  • 5.4.2 Recruitment Timelines
  • 5.4.3 Geographic Recruitment Distribution
• 5.5 Clinical Success and Failure Analysis
  • 5.5.1 Historical Success Rates
  • 5.5.2 Failure Drivers
  • 5.5.3 Trial Termination Trends
  • 5.5.4 Clinical Attrition Patterns
• 5.6 Regulatory Development Intelligence
  • 5.6.1 Fast Track Designations
  • 5.6.2 Breakthrough Therapy Designations
  • 5.6.3 Orphan and Special Regulatory Programs
• 5.7 Key Upcoming Clinical Milestones

6. Global Stroke Clinical Trials Landscape Report Segmentation Analysis

• 6.1 By Clinical Trial Phase
  • 6.1.1 Preclinical & Phase I
  • 6.1.3 Phase II
  • 6.1.4 Phase III
  • 6.1.5 Filed & Under Review
• 6.2 By Stroke Type
  • 6.2.1 Ischemic Stroke
    • 6.2.1.1 Thrombotic
    • 6.2.1.2 Embolic
  • 6.2.2 Hemorrhagic Stroke
  • 6.2.3 Transient Ischemic Attack
  • 6.2.4 Others
• 6.3 By Drug Type
  • 6.3.1 Thrombolytics
  • 6.3.2 Antiplatelets
  • 6.3.3 Anticoagulants
  • 6.3.4 Others
• 6.4 By Route of Administration
  • 6.4.1 Oral
  • 6.4.2 Intravenous
  • 6.4.3 Others

7. Probability of Success & Risk Analysis

• 7.1 Drug Development Risk Framework
• 7.2 Phase Transition Probability Analysis
  • 7.2.1 Preclinical to Phase I
  • 7.2.2 Phase I to Phase II
  • 7.2.3 Phase II to Phase III
  • 7.2.4 Phase III to Approval
• 7.3 Risk-Adjusted Pipeline Assessment
• 7.4 Attrition Rate Analysis
• 7.5 Clinical Risk Factors
• 7.6 Regulatory Risk Assessment
• 7.7 Commercial Risk Assessment
• 7.8 Probability-Weighted Revenue Forecasting
• 7.9 Scenario Modeling
  • 7.9.1 Base Case
  • 7.9.2 Optimistic Case
  • 7.9.3 Conservative Case

8. Launch Timeline & Commercial Potential

• 8.1 Expected Approval Timeline Analysis
• 8.2 Anticipated Product Launch Calendar
• 8.3 Launch Sequencing Assessment
• 8.4 Market Entry Timing Analysis
• 8.5 Peak Sales Potential Assessment
• 8.6 Revenue Forecast by Major Asset
• 8.7 Competitive Launch Overlap Analysis
• 8.8 Commercial Adoption Outlook
• 8.9 Long-Term Market Evolution

9. Competitive Pipeline Landscape

• 9.1 Competitive Environment Overview
• 9.2 Company-Wise Pipeline Strength Assessment
• 9.3 Leading Sponsors by Pipeline Size
• 9.4 Leading Sponsors by Clinical Stage
• 9.5 Innovation Leadership Analysis
• 9.6 Pipeline Concentration Assessment
• 9.7 Leader versus Challenger Positioning
• 9.8 Competitive Benchmarking Matrix
• 9.9 Emerging Entrants Analysis
• 9.10 Strategic Positioning Assessment

10. Geographic Analysis (Regional Level Only)

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Environment
  • 10.1.3 Innovation Ecosystem
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Environment
  • 10.2.3 Innovation Ecosystem
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Environment
  • 10.3.3 Innovation Ecosystem
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Environment
  • 10.4.3 Innovation Ecosystem
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Environment
  • 10.5.3 Innovation Ecosystem

11. Key Countries Analysis

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Deals & Investment Landscape

• 12.1 Licensing Agreements
• 12.2 Co-Development Collaborations
• 12.3 Research Partnerships
• 12.4 Mergers and Acquisitions
• 12.5 Venture Capital Investments
• 12.6 Private Equity Investments
• 12.7 Public Funding Initiatives
• 12.8 Strategic Alliance Trends
• 12.9 Investment Hotspots
• 12.10 Future Funding Outlook

13. Future Outlook & Strategic Insights

• 13.1 Genentech
  • 13.1.1 Pipeline Positioning
  • 13.1.2 Strategic Priorities
  • 13.1.3 Future Outlook
• 13.2 Boehringer Ingelheim
  • 13.2.1 Pipeline Positioning
  • 13.2.2 Strategic Priorities
  • 13.2.3 Future Outlook
• 13.3 F. Hoffmann-La Roche Ltd
  • 13.3.1 Pipeline Positioning
  • 13.3.2 Strategic Priorities
  • 13.3.3 Future Outlook
• 13.4 Novartis AG
  • 13.4.1 Pipeline Positioning
  • 13.4.2 Strategic Priorities
  • 13.4.3 Future Outlook
• 13.5 Bayer AG
  • 13.5.1 Pipeline Positioning
  • 13.5.2 Strategic Priorities
  • 13.5.3 Future Outlook
• 13.6 Johnson & Johnson
  • 13.6.1 Pipeline Positioning
  • 13.6.2 Strategic Priorities
  • 13.6.3 Future Outlook
• 13.7 Daiichi Sankyo
  • 13.7.1 Pipeline Positioning
  • 13.7.2 Strategic Priorities
  • 13.7.3 Future Outlook
• 13.8 Sanofi
  • 13.8.1 Pipeline Positioning
  • 13.8.2 Strategic Priorities
  • 13.8.3 Future Outlook
• 13.9 Novo Nordisk
  • 13.9.1 Pipeline Positioning
  • 13.9.2 Strategic Priorities
  • 13.9.3 Future Outlook
• 13.10 AstraZeneca PLC
  • 13.10.1 Pipeline Positioning
  • 13.10.2 Strategic Priorities
  • 13.10.3 Future Outlook
• 13.11 Merck & Co., Inc.
  • 13.11.1 Pipeline Positioning
  • 13.11.2 Strategic Priorities
  • 13.11.3 Future Outlook
• 13.12 GlaxoSmithKline plc
  • 13.12.1 Pipeline Positioning
  • 13.12.2 Strategic Priorities
  • 13.12.3 Future Outlook
• 13.13 Eli Lilly and Company
  • 13.13.1 Pipeline Positioning
  • 13.13.2 Strategic Priorities
  • 13.13.3 Future Outlook
• 13.14 AbbVie Inc.
  • 13.14.1 Pipeline Positioning
  • 13.14.2 Strategic Priorities
  • 13.14.3 Future Outlook
• 13.15 Future Pipeline Evolution Scenarios
• 13.16 Emerging Technology Assessment
• 13.17 Strategic Recommendations
• 13.18 Key Success Factors Through 2035

14. Methodology & Data Framework

• 14.1 Research Methodology
• 14.2 Data Collection Framework
• 14.3 Clinical Trial Data Sources
• 14.4 Company Disclosure Analysis
• 14.5 Regulatory Filing Assessment
• 14.6 Asset Inclusion Criteria
• 14.7 Pipeline Validation Methodology
• 14.8 Probability of Success Modeling Methodology
• 14.9 Revenue Forecasting Methodology
• 14.10 Competitive Benchmarking Methodology
• 14.11 Data Triangulation Process
• 14.12 Assumptions and Limitations
• 14.13 Quality Control Framework
• 14.14 Glossary and Definitions
• 14.15 Abbreviations and Acronyms